Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity - eBioMedicine

Frontiers Progress in construction of mouse models to investigate the pathogenesis and immune therapy of human hematological malignancy

RCSB PDB - 8BYU: Crystal Structure of HexaBody-CD38 Fab in complex with CD38

Crystal structure of CD38 in complex with daratumumab, a first-in-class anti -CD38 antibody drug for treating multiple myeloma - ScienceDirect

Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab. - Abstract - Europe PMC

Frontiers Therapeutic strategies for gastric cancer targeting immune cells: Future directions

Cancers, Free Full-Text

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. - Abstract - Europe PMC

CD38 treatment and PD-1/PD-L1. Nivolumab significantly reduced the

Ida H Hiemstra's research works Genmab, Copenhagen and other places

Ida H Hiemstra's research works Genmab, Copenhagen and other places